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exome sequencing in patients 
with chronic central serous 
chorioretinopathy
Rosa L. schellevis1, Myrte B. Breukink1, Christian Gilissen  2, Camiel J. F. Boon3, 
Carel B. Hoyng1, eiko K. de Jong1 & Anneke I. den Hollander  1,2
Chronic central serous chorioretinopathy (cCsC) is a multifactorial eye disease characterized by 
subretinal fluid accumulation that leads to vision loss. Clinically, cCSC is associated with stress, 
hypercortisolism and corticosteroid use, and is more frequent in males (80%) than in females (20%). 
Current genetic studies on cCsC have thus far focussed on common variants, but familial occurrence 
of cCsC also suggests a role for rare variants in the disease susceptibility. therefore, in this study, we 
performed exome sequencing of cCsC patients to elucidate the role of rare (protein-altering) variants 
in the disease. Exome sequencing was performed on 269 cCSC patients and 1,586 controls. Data were 
processed according to the Genome-Analysis-toolkit (GAtK) best practices. principal component 
analysis was performed to check for genetic ancestry and only unrelated subjects of european descent 
were retained. Burden, SKAT and SKAT-O tests were performed using 2 different grouping criteria. One 
group included protein-altering variants only, while the other contained synonymous and splice site 
variants as well. the gene-based analyses were performed using the sKAt R-package correcting for two 
principal components using two approaches; (1) on the entire cohort correcting for sex and (2) on males 
and females separately. Additionally, the gene-based associations of genes at previously reported 
cCSC loci were investigated. After filtering, the dataset contained 263 cCSC patients (208 males [79%]) 
and 1352 controls (671 males [50%]) carrying 197,915 protein-altering variants in 16,370 genes and 
330,689 exonic variants in 18,173 genes. Analysis stratified by sex identified significant associations 
with the PIGZ (psKAt = 9.19 × 10−7 & psKAt-o = 2.48 × 10−6), DUOX1 (psKAt = 1.03 × 10−6), RSAD1 
(psKAt = 1.92 × 10−7 & psKAt-o = 8.57 × 10−8) and LAMB3 (pBurden = 1.40 × 10−6 & psKAt-o = 1.14 × 10−6) 
genes in female cCsC patients, after correction for multiple testing. the number of rare variant carriers 
in these genes was significantly higher in the female cCSC cohort compared to female controls (45,5% 
vs. 18.5%, P = 1.92 × 10−6, oR = 3.67 [95% CI = 2.09–6.46]). No significant associations were identified 
in the entire cohort nor in the male patients. In this exome study on cCSC patients, we have identified 
PIGZ, DUOX1, RSAD1 and LAMB3 as potential new candidate genes for cCsC in females. the sex-
specific associations identified here suggest a possible interaction between rare genetic factors and sex 
for cCSC, but replication of these findings in additional cohorts of cCSC patients is necessary.
Central serous chorioretinopathy (CSC) is a vision-threatening eye disease characterized by serous fluid accumu-
lation between the neuroretina and retinal pigment epithelium (RPE), supposedly secondary to a dysfunctional 
choroid and outer blood-retina barrier of the RPE1. The incidence of CSC is estimated to be 1.7 in 100,000 in 
women and 9.9 in 100,000 in men with most cohorts confirming this ~80% male predominance1,2. Two distinct 
forms of CSC have been described, distinguished by the duration of symptoms and extend of the RPE alterations. 
Acute CSC usually resolves spontaneously within ~3 months, whereas in chronic CSC (cCSC) fluid accumula-
tion persists and more widespread RPE atrophy occurs1. The etiology of CSC is unknown, but associations with 
stress, hypertension and the use of corticosteroids have been described1. A genetic component for the disease 
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was suggested because of familial occurrence of CSC3,4, and so far a limited number of genetic studies have been 
performed for cCSC.
Candidate gene studies have described associations between cCSC and common single nucleotide polymor-
phisms (SNPs) in the CFH, ARMS2, CDH5 and NR3C2 genes5–8, as well as copy number variations (CNVs) of 
the C4B gene9. Additionally, the first genome-wide association study on cCSC confirmed the role of CFH in the 
disease10. Other genes suggested to be involved in the genetics of cCSC include CD46, CFHR1, CFHR4, KCNT2, 
TNFRS10A and VIPR210,11. So far, only common variants have been associated with cCSC, however, familial clus-
tering of cCSC has also hinted towards a possible role for rare variants in disease susceptibility3,4.
Therefore, to elucidate the role of rare (protein-altering) variants in cCSC we performed exome sequencing 
on 269 cCSC patients. We performed single-variant association and gene-based tests on the entire cohort and by 
stratifying the analyses for sex. Additionally, we investigated the gene-based associations of genes at loci that have 
previously been associated with cCSC. Here, we report new potential candidate genes for cCSC in females, and 
further broaden our knowledge on the disease etiology.
Materials and Methods
Library preparation and sequencing. cCSC patients. In this study, 269 cCSC patients who visited the 
outpatient clinic of the Department of Ophthalmology of the Radboud university medical center, Nijmegen, 
the Netherlands were included. Patients were diagnosed with cCSC based on multimodal retinal imaging as 
described previously6,10. DNA of cCSC patients, isolated from blood, was purified with the QIAamp DNA puri-
fication kit (Qiagen), according to manufacturer’s instructions. 3 µg of purified DNA was used as input for the 
SureSelectXT target enrichment system for Illumina paired-end multiplexed sequencing (Version B4, August 
2015, Agilent Technologies).
Library preparation was performed according to the manufacturer’s instructions. Samples were hybrid-
ized with the SureSelect All Exon V4 (Agilent Technologies) capture library and post-hybridization addition 
of the index tags was performed on the Dynabeads MyOne Streptavidin T1 beads (ThermoFisher Scientific). 
Midway and final quality checks were performed with Tapestation high sensitivity D1000 screentape (Agilent 
Technologies) and a Qubit dsDNA high sensitivity assay (ThermoFisher Scientific). A total of 8 samples was 
pooled for sequencing in one lane. Sequencing was performed at the Department of Genetics of Maastricht 
University Medical Center+, Maastricht, The Netherlands, using an Illumina HiSeq2000 with 2*100 bp chemistry.
Controls. As population controls, 1586 parents that were part of a large cohort of intellectual disability trios 
were used12; no ophthalmologic imaging was available for these individuals. Control samples were sequenced 
with the Agilent SureSelect V4 enrichment kit in a diagnostic setting at the Beijng Genomics Institute (BGI) in 
Copenhagen between August 2013 and March 2015. Sequencing was performed on an Illumina HiSeq instru-
ment with 101-bp paired-end reads12. The median coverage of the exomes of both cCSC patients and controls 
was 75X.
This study was performed according to the guidelines of the Declaration of Helsinki and was approved by the 
local ethics committee Commissie Mensgebonden Onderzoek (CMO) of the region Arnhem-Nijmegen. Written 
informed consent was obtained for all subjects involved in the study.
Variant calling. Bam to FastQC extraction was performed for both controls and cCSC patient data with 
Picard-tools (v 1.90). Files of patients and controls were processed together to minimize batch effects13. Duplicate 
reads were marked with Picard-tools and reads were aligned to the reference genome (GRCh37.p5 with alter-
nate haplotypes excluded) using BWA-MEM (version v.0.7.12). Sequencing data was processed according to 
the Genome-Analysis-Toolkit (GATK) best practices (v3.8). Briefly, base recalibration was performed using the 
following known sites: dbsnp version 144, Mills and 1000 G gold standard and 1000 G phase1 high confidence 
insertion/deletions (INDELs). Variant calling was performed with haplotypecaller in g.vcf mode specified on 
the SureSelect V4 regions flanked with 200 bp. Individual g.vcfs were merged into batches of 200 samples and 
joint genotyping on the whole cohort was performed per chromosome using genotypeGVCFs with the newQual 
option. Sites with a minimal average coverage of 15X in both the cCSC patients and control datasets were retained 
for downstream analyses.
Variant quality score recalibration (VQsR). Variant recalibration was performed with GATK (v3.8) 
using the recommended settings13. For SNPs, Hapmap3.3 and OmniExpress 2.5 chip sites were used as truth and 
training sets, while the 1000 G phase1 data was used for training only. For INDELs, the Mills and 1000 G gold 
dataset was used as truth and training sets. For both SNPs and INDELs “dbsnp v138 excluding sites after dbsnp 
v129 sites” were used to indicate known variants. The following arguments were used during the generation 
of the variant recalibration model for SNPs: Quality by Depth (QD), Mapping Quality (MQ), MQRankSum, 
ReadPosRankSum, Fisher strand (FS), Strand odds ratio (SOR), InbreedingCoeff, and MQCap = 60. For INDELs 
the MQ option was removed, as recommended. The variant recalibration model was applied to the dataset for 
SNPs and INDELs separately and the data was filtered based on the 99.5 and 99 sensitivity tranche, respectively.
Population stratification, Cryptic relatedness and Sex-check. All variants overlapping with the 
Hapmap3 data were extracted and combined with the original Hapmap3 data containing individuals of various 
genetic ancestries. The merged dataset was pruned using PLINK (v1.90b3y), with a window size of 50 kb, step-
size of 5 kb and variant inflation factor of 2. Principal component analysis (PCA) was performed on the data to 
account for population admixture. The first 2 PCA components were plotted with R (v 3.2.0), and ancestry labels 
were added to the Hapmap data. After filtering only individuals from European descent were retained (Fig. S1 in 
Document S1).
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To assess cryptic relatedness between individuals in the dataset, kinship coefficients were calculated with 
KING (v2.0)14. Proportion of zero identity by state (IBS) was plotted against the estimated kinship coefficient 
with R (v 3.2.0) (Fig. S2 in Document S1). Samples were removed that had a kinship coefficient indicative of being 
either first degree (0.177–0.354), second degree (0.177–0.0884) or third degree (0.0884–0.0442) relatives. Finally, 
reported sex was compared with the data available for the X chromosome using the sex-check option in PLINK, 
with a threshold of F < 0.35 for women and F > 0.7 for men.
Variant filtering. Variants located in low complexity regions of the genome were removed15. Multiallelic var-
iants were extracted with VCFtools (v0.1.13) and split using the splitMultiallelic and LeftAlingandTrimVariants 
option in GATK (v3.8). After splitting, biallelic and multiallelic SNPs and INDELs were combined and tested for 
Hardy-Weinberg equilibrium P > 1 × 10−8 and a minor allele count of 1. Variants from the adult-onset cancer 
genes captured in the American College of Medical Genetics and Genomics recommendations for incidental 
findings (BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, MUTYH) were removed to reduce the risk of secondary 
findings16. Remaining variants were annotated with TabAnno (https://github.com/zhanxw/anno). In order to 
perform the downstream gene analysis, two different groupfiles were made using a Python script (available on 
request). The protein-altering variant groupfile contained nonsynonymous, stop gain/loss, start gain/loss, codon 
gain/loss, frameshift and essential splice site variants, while the exonic groupfile included both protein-altering 
variants and synonymous, exon and variants in the complete splice site.
statistical analysis. Data was converted to binary PLINK files and imported into the SKAT R-package 
(v. 1.2.1)17,18. As the SKAT package does not offer a function to analyze a large set of single variants, one large 
“dummy” geneset was generated containing all the variants in the input file. The association of each variant was 
calculated with a loop through the “dummy” geneset (Script File S1). The SKAT R-package uses the efficient 
resampling method to also include extremely rare variants in the analysis17. The SKAT null model adjusted for 
small sample size was performed for a binary phenotype correcting for two principal components and sex (for 
the entire cohort) with the resampling method “bootstrap.fast”. The generated file was also used to calculate the 
variant weights based on minor allele frequency using the “Get_Logistic_Weights” function of the SKAT package 
(v. 1.2.1)17,18.
Next, a minor allele frequency (MAF) weighted Burden, SKAT, and SKAT-O analysis was performed with the 
“SKATBinary.SSD.All” option. These analyses were performed on either the entire cohort or the cohort stratified 
by sex using the protein-altering and exonic groupfiles. The default settings were used for kernel (linear.weighted), 
imputation methods (bestguess), number of resampling (2 × 106) and p-value calculation (hybrid). Only genes 
with at least two variants were retained and multiple testing correction was performed using Bonferroni correc-
tion. Plots were generated with the R-package CMplot. An example of the gene-based test pipeline is available in 
Script File S1. Sanger sequencing was performed to confirm the presence of the variants in the top- and sugges-
tive genes of the different gene-based tests in the cCSC patients (P < 5 × 10−5). Additionally, Burden, SKAT and 
SKAT-O p-values of previously associated cCSC genes and genes in their 100 kb up- and downstream region were 
extracted from the dataset.
The number of rare variant carriers (MAF < 0.05) in the four identified cCSC candidate genes was counted 
per gene in female and male cCSC patients and controls. The carrier and non-carrier groups were compared 
between controls and cCSC patients using a Chi-square test or Fisher’s exact test when at least 25% of the cells 
had an expected count <5. Odds ratios for single variants in the candidate genes were calculated using the Firth 
corrected likelihood method in SAS (v9.4)19, when variants were significantly associated with cCSC, because the 
SKAT single variant analysis only provides P-values and no risk estimates. Haplotypes in the LAMB3 gene were 
constructed with the haplo.stats R-package as described before10,20.
ethics approval and consent to participate. This study was performed according to the guidelines 
of the Declaration of Helsinki and was approved by the local ethics committee. Written informed consent was 
obtained for all subjects involved in the study.
Results
Quality control. In this study, 269 cCSC patients and 1586 controls were analysed by exome sequencing. 
Among these samples 232 controls and six cCSC patients were not of European descent, and were therefore 
excluded from downstream analysis. Additionally, three control samples were removed due to cryptic relatedness 
(n = 2) or uncertain sex based on the X-chromosome data (n = 1). After individual quality control the dataset 
contained 263 cCSC patients (208 males [79%]) and 1352 controls (671 males [50%]). For these individuals, 
joint genotyping with GATK resulted in a dataset containing 746,264 SNPs and 45,048 INDELs. Of these 3,793 
SNPs and 1,661 INDELs were multiallelic, and were split. Additional quality control included HWE filtering 
(P = 1 × 10−8) and removal of the low complexity regions of the genome15. Finally, a total of 579,602 variants 
remained for downstream analysis, of which 547,595 were SNPs and 32,007 were INDELS.
Unbiased single variant association and gene-based analyses. Single variant association analysis 
corrected for sex and two principal components did not identify any genome-wide significant hits in the entire 
datasets, nor in the datasets stratified by sex (Fig. S3 in Document S1). To increase power to detect associations, 
gene-based analyses using the Burden, SKAT and SKAT-O tests were performed. These analyses were carried out 
on the entire cohort and on male and female cohorts stratified by sex, testing either all protein-altering variants 
or using all exonic variants. The number of genes and variants included in the gene-based analyses is described 
in Table 1.
In the protein-altering variant analysis, genome-wide significant associations with the PIGZ (PSKAT = 9.19 × 
10−7 & PSKAT-O = 2.48 × 10−6) and DUOX1 (PSKAT = 1.03 × 10−6) genes were identified in females (Table 2, 
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Fig. 1A). Additionally, suggestive associations in the protein-altering analysis (P < 5 × 10−5) were identified in the 
entire cohort, as well as the male and female cohort for NOP14, RSPO2, LAMB3, TDGF1 and RSL1D1 (Fig. 1A, 
Table S2 and Fig. S4 in Document S1). Gene-based analyses of the exonic variants identified genome-wide signif-
icant associations in the RSAD1 (PSKAT = 1.92 × 10−7 & PSKAT-O = 8.57 × 10−8) and LAMB3 (PBurden = 1.40 × 10−6 & 
PSKAT-O = 1.14 × 10−6) genes in the female cohort (Table 2, Fig. 1B). Gene-based analysis of the exonic variant on 
the entire cohort and the male cohort did not identify any genome-wide associations. Suggestive hits for the entire 
cohort and the stratified male and female cohorts were identified in ALX1, NOP14, G3BP1, RNF144A, C5orf63, 
NOB1, LOC283332, ZNF713, SPATA7, C1QL3, GAPVD1, ZNF300P1, LIPH and OR5H14 (Fig. 1B, Table S2 and 
Fig. S4 in Document S1).
Rare variant carrier frequency in PIGZ, DUOX1, LAMB3 and RSAD1 in cCSC patients and controls. 
Gene-based analyses identified four cCSC-associated candidate genes in the female cohort. An overview of all 
variants found in PIGZ, DUOX1, LAMB3 and RSAD1 in females is presented in Table S2. The PIGZ gene-based 
association was explained by 14 rare (MAF < 0.05) and 4 common (MAF > 0.05) nonsynonymous variants. The 
percentage of rare variant carriers was higher in the female cCSC patient group compared to the female con-
trols (Table 3, P = 0.014, Odds ratio (OR) = 3.67 [95% confidence interval (CI) = 1.42–9.47]). The p.A124V var-
iant in PIGZ was individually associated with cCSC in females (P = 0.0003, OR = 16.40 [95% CI = 3.64–73.94]) 
(Table S2).













All individuals 197,915 16,370 3.05 × 10−6 330,689 18,173 2.75 × 10−6
Males 135,468 15,083 3.31 × 10−6 232,667 17,348 2.88 × 10−6
Females 123,898 14,935 3.35 × 10−6 215,244 17,370 2.88 × 10−6
Table 1. Number of variants and genes included in the gene-based analyses. #Only genes with more than 2 
variants were retained and used for Bonferroni correction.
Gene Variants Burden p-value SKAT p-value SKAT-O p-value
PIGZ Protein-altering 6.99 × 10−3 9.19 × 10−7# 2.48 × 10−6#
DUOX1 Protein-altering 7.18 × 10−3 1.03 × 10−6# 4.23 × 10−6
RSAD1 Exonic 7.14 × 10−5 1.92 × 10−7* 8.57 × 10−8*
LAMB3 Exonic 1.40 × 10−6* 4.51 × 10−6 1.14 × 10−6*
Table 2. Significant gene-based association results for the female cCSC cohort using the Burden, SKAT and 
SKAT-O tests. #Significant after Bonferroni correction for 14,935 genes; P ≤ 3.35 × 10−6. *Significant after 
Bonferroni correction for 17,370 genes; P ≤ 2.88 × 10−6.
Figure 1. Manhattan plot of gene-based analysis in female cCSC patients. Burden (blue), SKAT (green) and 
SKAT-O (purple) association results are depicted for the female cohort including 55 cCSC patients vs. 681 
controls, using the protein-altering (A) and exonic (B) group files. The dark horizontal line indicates the 
significance threshold after correction for multiple testing: 0.05/17,370 genes = 2.88 × 10−6 (A), 0.05/14,935 
genes = 3.35 × 10−6 (B), while the dotted line indicates the suggestive threshold of P = 5 × 10−5.
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The DUOX1 gene-based association was composed of 12 rare and 2 common nonsynonymous variants and 1 
rare stop-gain variant. Of the rare variants, 3 were found in the cCSC group, whereas 11 were found in the con-
trol group. The percentage of carriers was significantly higher in the cCSC group compared to controls (Table 3, 
P = 0.039, OR = 3.74 [95% CI = 1.19–11.77]) The p.R925W variant was individually associated with cCSC 
(P = 0.03, OR = 62.69 [95% CI = 1.52− > 999.99]), and was only found in the female cCSC group (Table S2).
In the LAMB3 gene, a total of 49 variants was observed in females. These variants included 31 nonsynony-
mous, 13 synonymous, 3 intronic variants near splice sites and 2 stop-gain variants. Three of the synonymous 
variants were common, while the remaining 46 variants were rare. In the control group 93 individuals (13.7%) 
carried at least one LAMB3 rare variant, while 17 (30.9%) female cCSC patients carried one or more rare vari-
ants in LAMB3 (Table 3, P = 0.00056, OR = 2.83 [95% CI = 1.53–5.22]). Haplotype analysis identified a signifi-
cant association with cCSC for a haplotype carrying 7 variants in LAMB3 (p.S97S, p.N181D, p.V527M, p.Y588Y, 
p.S708S, p.N690S, p.A926D) which had a frequency of 7.3% in the cCSC patients and 1.6% in the control cohort 
(Table S3, P = 7.22 × 10−5, OR = 6.60 [95% CI = 2.61–16.67]).
A total of 11 variants was present in RSAD1 in females, of these 9 were nonsynonymous (7 rare, 2 common) 
variants, 1 was a common synonymous variant, and 1 was a rare intronic variant. The percentage of rare variant 
carriers was higher among female cCSC patients, compared to the control group (Table 3, P = 0.017, OR = 7.80 
[95% CI = 1.81–33.55]). Three variants were only observed in the patient group (p.P250L, p.V299I, p.R317Q).
In total, 18.5% of the female control individuals carried at least one rare variant in PIGZ, DUOX1, LAMB3 or 
RSAD1, whereas this percentage was 45.5% in the female cCSC patients. The percentage of rare variant carriers 
in these genes was significantly higher in the female cCSC patients group compared the control group (Table 3, 
P = 1.92 × 10−6, OR = 3.67 [95% CI = 2.09–6.46]). In males, no differences in the percentage of carriers of PIGZ, 
DUOX1, LAMB3 or RSAD1 rare variants were observed between controls and cCSC patients (Table S4). Also, the 
total percentage of carriers of at least one variant in these 4 genes was not different in males (Table S4).
Gene-based association of genes located in known cCsC loci. Previous candidate gene and 
genome-wide association studies identified common, mostly non-coding variants in or near several genes in 
cCSC. We aimed to determine whether rare coding variants in these genes are associated with cCSC, since 
such associations could point towards casual genes in the known cCSC loci. Genes at previously associated 
cCSC loci and genes within ±100 kb of the top-associated variant were extracted from the dataset including 
the ARMS2-HTRA1, C4-RCCX, CD46, CDH5, KCNT2-CFH-CFHR1/4, NR3C2, TNFRS10A and VIPR2 loci. In 
total, 56 genes were located in these regions, of which 39 genes contained at least 2 protein-altering variants and 
44 genes had at least 2 variants in the exonic regions. The gene-based association results of these genes were 
extracted from the genome-wide analysis. However, no associations were identified between these genes and 
cCSC after correction for multiple testing (Table S5, Threshold P < 0.00114 [corrected for 44 genes in the exonic 
variant analysis] and P < 0.00128 [corrected for 39 genes in the protein-altering variant analysis]), indicating that 
rare coding variants at the known cCSC loci are not associated with cCSC in this cohort.
Discussion
In this study, in order to increase our knowledge and understanding of the genetics of cCSC, we performed exome 
sequencing on a cohort of cCSC patients. Using a gene-based approach, we identified four potential new candi-
date genes for the disease in female cCSC patients specifically.
Due to a relative small sample size this study had limited power to identify single-variant associations, espe-
cially for rare variants, therefore, three different gene-based analyses with varying assumptions were performed. 
Previous studies have shown that the CFH gene carried both protective and risk-conferring variants5,6, therefore, 
we used the SKAT test, which assumes variants within a gene can have both directions of effect. The Burden test 
on the other hand relies on the assumption that all variants in a gene have the same direction of effect, and the 
SKAT-O test combines both assumptions into one test18. The gene-based analyses were performed using two dif-
ferent inclusion criteria. One analysis contained protein-altering variants only, since they are most likely to affect 
protein function. The other analysis contained all exonic variants, including synonymous (silent) variants and 
splice site variants, of which the effect on protein function is more difficult to predict. Nevertheless, such variants 
may alter gene expression levels and were therefore included in the analysis21. In the female cohort we identified 
a significant burden of protein-altering variants in two genes (PIGZ and DUOX1) and a significant burden of 




Nr. carriers in controls 
(ntotal = 681)
Nr. carriers in cCSC patients 
(ntotal = 55) P-value OR (95% CI)
PIGZ 14 22 (3.2%) 6 (10.9%) 0.014 3.67 (1.42–9.47)
DUOX1 13 14 (2.1%) 4 (7.3%) 0.039 3.74 (1.19–11.77)
LAMB3 46 93 (13.7%) 17 (30.9%) 5.57 × 10–4 2.83 (1.53–5.22)
RSAD1 8 5 (0.7%) 3 (5.5%) 0.017 7.80 (1.81–33.55)
Variant in 
1 or more 
genes
126 (18.5%) 25 (45.5%) 1.92 × 10−6 3.67 (2.09–6.46)
Table 3. Female carriers of rare variants (MAF < 0.05) in PIGZ, DUOX1, LAMB3 and RSAD1. Nr. number; 
P-values are calculated with Chi-square test or Fisher’s exact when at least 25% of the cells had an expected 
count <5.
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Nearly half of the females in the cCSC cohort carried at least one variant in the four identified cCSC candidate 
genes (45.5%), while this number was significantly lower in the female control cohort (18.5%, P = 1.92 × 10−6). 
Carrying a rare variant in one of these genes increases the risk for developing cCSC 3.7-fold in females, while 
carrying a variant in RSAD1 even increases risk 7.8-fold. Notably, a number of high-risk variants were identified 
in the gene-based tests, including the p.A124V variant in PIGZ (P = 0.0003, OR = 16.40 [95% CI = 3.64–73.94]) 
and the p.R925W variant in the DUOX1 gene (P = 0.03, OR = 62.69 [95% CI = 1.52− > 999.99]), and three vari-
ants (p.P250L, p.V299I, p.R317Q) in RSAD1 were observed only in the patient group but not in the controls. The 
percentage of carriers of rare variants in the PIGZ, DUOX1, LAMB3 and RSAD1 genes was not different between 
male cCSC patients and controls (Table S4, 15.9% vs. 20.4%, respectively, P = 0.146), indicating that the observed 
associations with cCSC are sex-specific. Since in our exome sequencing dataset of 263 patients only 55 were 
female, replication in an independent female cCSC cohort is necessary to substantiate these findings.
Interestingly, genome-wide significant associations were only observed in female cCSC patients but not in 
the males. The enrichment of rare variants in these genes in females is likely not due to population stratification, 
sequencing artefacts or the presence of related individuals, because stringent quality control was performed to 
avoid these confounders. It remains unclear why no associations in the male cCSC cohort were observed, despite 
accounting for the largest proportion of the cohort. One could hypothesize that cCSC is more genetically het-
erogeneous in males, and that a larger sample size is therefore necessary to identify associations in this group. 
The biological mechanism behind these sex-specific associations remains to be elucidated, but sex-biased gene 
expression or regulation could be one of the contributing factors22,23. Interactions between sex and genetics have 
been described for other complex traits such as hypertension, schizophrenia and juvenile idiopathic arthritis23–25, 
and for cCSC the previously described CDH5 association was observed in males only7. Future genetic studies on 
cCSC, should focus on increasing samples size, but also should take sex-stratification into account, to further 
elucidate a possible interaction between sex and genetics.
For cCSC specifically, an interaction between genetic variants and sex hormone regulation and expression 
seems likely, since the association of cCSC with the stress axis, hypercortisolism and the use of corticosteroids 
has been described extensively, and pregnancy is known to increase the risk of CSC in females1,26. An interaction 
with the steroid hormone system has already been described for LAMB3 and DUOX127,28. For the LAMB3 gene, 
Zhao et al. described upregulation of gene expression in endometrial biopsies after stimulation of 17β-estradiol 
and progesterone, both hormones involved mainly in the female reproductive system27; for the DUOX1 gene, Ko 
et al. described increased expression after testosterone stimulation in keratinocytes28. Future studies might study 
the effect of variants in these genes on their response to hormonal differences in cellular models. Additionally, all 
four identified candidate genes are expressed in different tissues of the eye including the retina and RPE (Fig. S5 
in Document S1)29. In light of the cCSC phenotype, for all four genes the effect of the identified variants on the 
disease mechanisms remains to be determined. Additionally, future experiments could focus on determining if a 
steroid hormone response is also present in the retina, RPE and/or choroid for these genes, and if the identified 
rare variants might alter this response.
Conclusions
In this exome sequencing study on a cohort of cCSC patients and population controls, we identified PIGZ, 
DUOX1, LAMB3 and RSAD1 as potential new candidate genes for cCSC in females specifically. Our results sug-
gest that the contribution of rare genetic risk variants might be different between the sexes and that the cCSC 
disease mechanism might differ between males and females. Replication of the current findings in larger cCSC 
cohorts is necessary, and further genetic studies and clinical trials on cCSC could take an interaction component 
between sex and genetics into account for cCSC.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on rea-
sonable request.
References
 1. Daruich, A. et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48, 
82–118, https://doi.org/10.1016/j.preteyeres.2015.05.003 (2015).
 2. Kitzmann, A. S., Pulido, J. S., Diehl, N. N., Hodge, D. O. & Burke, J. P. The incidence of central serous chorioretinopathy in Olmsted 
County, Minnesota, 1980–2002. Ophthalmology 115, 169–173, https://doi.org/10.1016/j.ophtha.2007.02.032 (2008).
 3. van Dijk, E. H. C. et al. Familial Central Serous Chorioretinopathy. Retina, https://doi.org/10.1097/IAE.0000000000001966 (2017).
 4. Weenink, A. C., Borsje, R. A. & Oosterhuis, J. A. Familial chronic central serous chorioretinopathy. Ophthalmologica. Journal 
international d’ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 215, 183–187, https://doi.
org/10.1159/000050855 (2001).
 5. Miki, A. et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. 
Ophthalmology 121, 1067–1072, https://doi.org/10.1016/j.ophtha.2013.11.020 (2014).
 6. de Jong, E. K. et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular 
degeneration. Ophthalmology 122, 562–570, https://doi.org/10.1016/j.ophtha.2014.09.026 (2015).
 7. Schubert, C. et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Human mutation 
35, 859–867, https://doi.org/10.1002/humu.22551 (2014).
 8. van Dijk, E. H. et al. Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic 
Central Serous Chorioretinopathy. JAMA ophthalmology, https://doi.org/10.1001/jamaophthalmol.2017.0245 (2017).
 9. Breukink, M. B. et al. Genomic Copy Number Variations of the Complement Component C4B Gene Are Associated With Chronic 
Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci 56, 5608–5613, https://doi.org/10.1167/iovs.15-17343 (2015).
 10. Schellevis, R. L. et al. Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association 
Study. JAMA Ophthalmol, https://doi.org/10.1001/jamaophthalmol.2018.3190 (2018).
7Scientific RepoRts |          (2019) 9:6598  | https://doi.org/10.1038/s41598-019-43152-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 11. Hosoda, Y. et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous 
chorioretinopathy. Proc Natl Acad Sci USA 115, 6261–6266, https://doi.org/10.1073/pnas.1802212115 (2018).
 12. Lelieveld, S. H. et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat Neurosci 19, 
1194–1196, https://doi.org/10.1038/nn.4352 (2016).
 13. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome research 20, 1297–1303, https://doi.org/10.1101/gr.107524.110 (2010).
 14. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867–2873, https://doi.
org/10.1093/bioinformatics/btq559 (2010).
 15. Li, H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics 30, 2843–2851, https://
doi.org/10.1093/bioinformatics/btu356 (2014).
 16. Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics 
in medicine: official journal of the American College of Medical Genetics 15, 565–574, https://doi.org/10.1038/gim.2013.73 (2013).
 17. Lee, S., Fuchsberger, C., Kim, S. & Scott, L. An efficient resampling method for calibrating single and gene-based rare variant 
association analysis in case-control studies. Biostatistics 17, 1–15, https://doi.org/10.1093/biostatistics/kxv033 (2016).
 18. Lee, S. et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-
exome sequencing studies. American journal of human genetics 91, 224–237, https://doi.org/10.1016/j.ajhg.2012.06.007 (2012).
 19. Firth, D. Bias Reduction of Maximum-Likelihood-Estimates. Biometrika 80, 27–38, https://doi.org/10.2307/2336755 (1993).
 20. Sinnwell, J. P. & Schaid D. J. haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous; 
R package version 1.7.7, https://CRAN.R-project.org/package=haplo.stats.
 21. Sauna, Z. E. & Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12, 
683–691, https://doi.org/10.1038/nrg3051 (2011).
 22. Ellegren, H. & Parsch, J. The evolution of sex-biased genes and sex-biased gene expression. Nat Rev Genet 8, 689–698, https://doi.
org/10.1038/nrg2167 (2007).
 23. Ober, C., Loisel, D. A. & Gilad, Y. Sex-specific genetic architecture of human disease. Nat Rev Genet 9, 911–922, https://doi.
org/10.1038/nrg2415 (2008).
 24. Haasnoot, A. J. W. et al. Identification of an Amino Acid Motif in HLA-DRbeta1 That Distinguishes Uveitis in Patients With Juvenile 
Idiopathic Arthritis. Arthritis Rheumatol 70, 1155–1165, https://doi.org/10.1002/art.40484 (2018).
 25. Shifman, S. et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia 
only in women. PLoS Genet 4, e28, https://doi.org/10.1371/journal.pgen.0040028 (2008).
 26. Liu, B., Deng, T. & Zhang, J. Risk Factors for Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis. Retina 36, 
9–19, https://doi.org/10.1097/IAE.0000000000000837 (2016).
 27. Zhao, Y. et al. The impact of luteal phase support on gene expression of extracellular matrix protein and adhesion molecules in the 
human endometrium during the window of implantation following controlled ovarian stimulation with a GnRH antagonist 
protocol. Fertil Steril 94, 2264–2271, https://doi.org/10.1016/j.fertnstert.2010.01.068 (2010).
 28. Ko, E. et al. Testosterone stimulates Duox1 activity through GPRC6A in skin keratinocytes. J Biol Chem 289, 28835–28845, https://
doi.org/10.1074/jbc.M114.583450 (2014).
 29. Bryan, J. M. et al. Identifying core biological processes distinguishing human eye tissues with precise systems-level gene expression 
analyses and weighted correlation networks. Human Molecular Genetics, ddy239, https://doi.org/10.1093/hmg/ddy239 (2018).
Acknowledgements
We would like to thank Simone van den Heuvel for her help with the library preparation of the cCSC samples. 
Also, we would like to thank Marc Pauper and Stefan Lelieveld for the usage of their scripts and Dimitra 
Zafeiropoulou for her bio-informatics support. This study was supported by the Macula Vision Research 
Foundation and the Radboud Institute for Molecular Life Sciences.
Author Contributions
R.L.S. performed library preparation of the cCSC samples, performed all bioinformatics analyses including 
variant calling, filtering, and statistical analysis and drafted the manuscript. M.B.B. was instrumental in collecting 
DNA samples from cCSC patients. C.B.H. collected DNA samples and supervised M.B.B. and C.G. provided 
the control samples used in this study and offered bioinformatics support. C.J.F.B. collected DNA samples, 
supervised M.B.B. and performed clinical grading of the cCSC patients. E.K.d.J. and A.I.d.H. obtained funding 
for the research and were responsible for design of the study, critical revisions of the manuscript and supervision 
of R.L.S. All authors provided critical feedback on the manuscript and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43152-3.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
